Share This Page
Drug Price Trends for DESVENLAFAXINE ER
✉ Email this page to a colleague
Average Pharmacy Cost for DESVENLAFAXINE ER
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DESVENLAFAXINE ER 100 MG TAB | 63304-0192-30 | 3.53558 | EACH | 2024-12-18 |
| DESVENLAFAXINE ER 50 MG TAB | 63304-0191-30 | 3.62939 | EACH | 2024-12-18 |
| DESVENLAFAXINE ER 50 MG TAB | 63304-0191-30 | 3.72217 | EACH | 2024-11-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
DESVENLAFAXINE ER Market Analysis and Financial Projection
Market Analysis and Price Projections for Desvenlafaxine ER
Introduction to Desvenlafaxine ER
Desvenlafaxine, marketed under the brand name Pristiq among others, is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of major depressive disorders in adults. Here, we will delve into the market analysis and price projections for Desvenlafaxine ER.
Market Overview
The global market for Desvenlafaxine ER is part of the broader depression treatment market, which is experiencing significant growth. As of 2022, the depression treatment market was valued at approximately $10.1 billion and is projected to expand at a CAGR of 5.2% to reach $16.8 billion by 2032[3].
Market Segmentation
The Desvenlafaxine market can be segmented based on type, application, and region.
- Type: The market includes various dosages of Desvenlafaxine ER, such as 25 mg, 50 mg, and 100 mg oral tablets.
- Application: Desvenlafaxine is commonly used for treating major depressive disorders, anxiety, bipolar disorder, and other mental health conditions.
- Region: The market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. Each region has its own set of contributing countries and revenue shares[1].
Market Size and Growth
The global Desvenlafaxine market is anticipated to witness significant growth in the near future. Here are some key metrics:
- Historical Data: From 2019 to 2023, the market has shown steady growth.
- Forecast Period: The market size is estimated to grow from 2024 to 2031, with a compound annual growth rate (CAGR) that indicates robust expansion[1].
Regional Analysis
The regional analysis is crucial for understanding the market's geographical distribution.
- North America: This region is a significant contributor to the global Desvenlafaxine market, driven by high prevalence rates of mental health disorders and advanced healthcare infrastructure.
- Europe: Europe also holds a substantial share, with many countries investing heavily in mental health services.
- Asia Pacific: This region is expected to grow rapidly due to increasing awareness and funding for mental health treatments[1].
Key Players and Competitive Landscape
Several key players are active in the Desvenlafaxine market, including:
- Adroit PharmaChem
- Teva
- Alembic Pharmaceuticals: Notably, Alembic Pharmaceuticals received FDA approval for its Desvenlafaxine ER capsules in 2018, which has positively impacted the market[1][3].
These companies are focusing on strategy building, product portfolio expansion, and business growth in the global market.
Price Projections
The prices of Desvenlafaxine ER vary based on dosage, quantity, and the pharmacy.
Generic vs. Brand Name
- Generic Desvenlafaxine: The cost for a generic version of Desvenlafaxine (as succinate) 50 mg oral tablet, extended release, is around $75 for a supply of 30 tablets[2].
- Brand Name (Pristiq): The cost for Pristiq (as succinate) 50 mg oral tablet, extended release, is approximately $225 for a supply of 14 tablets[5].
Price Variations
Prices can vary significantly depending on the quantity and pharmacy:
| Dosage | Quantity | Price Range |
|---|---|---|
| 25 mg | 30 tablets | $96.68 - $97.19[2] |
| 50 mg | 30 tablets | $75.07 - $97.19[2] |
| 100 mg | 30 tablets | $97.55 - $157.52[2] |
Discounts and Assistance
Patients can benefit from discounts, coupons, and copay cards, which can significantly reduce the cost. For example, using the Drugs.com discount card can help consumers pay the lower end of the price range[2][5].
Market Drivers and Opportunities
Several factors are driving the growth of the Desvenlafaxine market:
- Increasing Prevalence of Mental Health Disorders: According to the World Health Organization (WHO), there has been a 13% increase in mental health conditions over the last decade, which is driving the demand for effective treatments[3].
- Government Funding and Healthcare Policies: Governments are increasing funding for mental health services, which is boosting the market[3].
- Novel Drug Approvals: Recent approvals of new drugs and therapies, such as Alembic Pharmaceuticals' Desvenlafaxine ER capsules, are positively impacting the market[3].
Market Restraints
Despite the growth, there are some restraints to consider:
- Side Effects and Safety Concerns: Desvenlafaxine can have side effects such as systolic orthostatic hypotension, especially in elderly patients, and clinically significant hyponatremia[4].
- Regulatory Challenges: The pharmaceutical industry is heavily regulated, and any changes in regulatory policies can affect the market.
Technological and ESG Trends
The market is also influenced by technological advancements and environmental, social, and governance (ESG) factors:
- Technological Trends: Advances in drug delivery systems and manufacturing processes can improve the efficacy and safety of Desvenlafaxine ER.
- ESG Analysis: Companies are increasingly focusing on ESG factors, which can impact their reputation and market performance[1].
Consumer Behavior Analysis
Consumer behavior plays a crucial role in the market dynamics:
- Awareness and Acceptance: Increasing awareness about mental health and the acceptance of treatments are driving the demand for Desvenlafaxine ER.
- Patient Assistance Programs: Many pharmaceutical companies offer patient assistance programs, which can influence consumer behavior and market growth[1].
Key Takeaways
- The Desvenlafaxine market is part of the growing depression treatment market, expected to expand at a CAGR of 5.2% from 2022 to 2032.
- The market is segmented by type, application, and region, with North America and Europe being significant contributors.
- Key players are focusing on strategy building and product portfolio expansion.
- Prices vary between generic and brand-name versions, with discounts and assistance programs available.
- Market growth is driven by increasing prevalence of mental health disorders, government funding, and novel drug approvals.
FAQs
What is Desvenlafaxine ER used for?
Desvenlafaxine ER is used primarily for the treatment of major depressive disorders in adults. It is also used for conditions such as anxiety and bipolar disorder.
How much does Desvenlafaxine ER cost?
The cost of Desvenlafaxine ER varies. For a generic version, a supply of 30 tablets of 50 mg can cost around $75. The brand name version, Pristiq, can cost approximately $225 for 14 tablets.
What are the side effects of Desvenlafaxine ER?
Common side effects include systolic orthostatic hypotension, especially in elderly patients, and clinically significant hyponatremia.
Which companies are key players in the Desvenlafaxine market?
Key players include Adroit PharmaChem, Teva, and Alembic Pharmaceuticals.
How is the Desvenlafaxine market expected to grow?
The market is expected to grow significantly, driven by increasing prevalence of mental health disorders, government funding, and novel drug approvals, with a projected CAGR of 5.2% from 2022 to 2032.
Sources
- Cognitive Market Research: Global Desvenlafaxine Market Report 2024 Edition.
- Drugs.com: Desvenlafaxine Prices, Coupons, Copay Cards & Patient Assistance.
- Future Market Insights: Depression Treatment Industry: Trends & Opportunities.
- DrugBank: Desvenlafaxine: Uses, Interactions, Mechanism of Action.
- Drugs.com: Pristiq Prices, Coupons, Copay Cards & Patient Assistance.
More… ↓
